Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] Hanwha Ocean (042660) – Kiwoom | Merchant Earnings Growth · 2H Order Momentum · US Naval Defense / 2026-07-15 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q4 2025 Earnings Presentation / 2026-01-23 IR Room
  • [Research] Alteogen (196170) – Shinhan Securities | First UK Patent Ruling Favors Merck · Positive Read-across to Global Disputes · Pipeline Out-Licensing Ahead / 2026-02-23 Research
  • [Research] SK hynix (000660 / SKHY) – SK Securities | AI Memory · NAND Tiering · Earnings Re-rating / 2026-02-24 Research
  • [Research] LigaChem Biosciences (141080) – IBK Securities | Enhertu Resistance · Clinical Readouts · Tech Transfer / 2025-11-27 Research
  • [Research] LIG D&A (079550) – Eugene Investment & Securities | Global Demand Spillover · CapEx Expansion · Long-term Compounding / 2026-08-07 Research
  • [Research] Alteogen (196170) – Hana Securities | New ALT-B4 Deal Signed · Qlex Prescription Surge · SC Conversion Acceleration / 2026-08-06 Research
  • [Research] SK hynix (000660 / SKHY) – DS Investment | Server Memory Demand · HBM3E Pricing · Margin Expansion / 2026-01-30 Research

[Research] Samsung SDI (006400) – Shinhan Securities | North America ESS Surges · BBU Demand Expansion · Turnaround Visibility / 2026-04-20

Posted on April 20, 2026August 22, 2026 By ksb220805@gmail.com

Brokerage : Shinhan Securities

Analyst : Jin-myung Lee, Myung-joo Kim

Investment Rating : BUY (Maintained)

Target Price : KRW 580,000 (Raised)

Core Momentum : Surging US utility-scale ESS demand and expanding small-battery BBU applications, combined with 2H26 European EV utilization recovery and North American LFP additions, support a structural earnings turnaround.

📊 1. [Valuation & Key Financial Metrics]

  • Investment Rating & Target Price: BUY (Maintained), Target Price KRW 580,000 (Raised by +47% reflecting upward earnings revisions and target peer multiple expansion)
  • Market Data (As of 2026-04-17): Current Price KRW 513,000 (Upside Potential 13.1%), Market Cap KRW 41.34 Trillion, Shares Outstanding 80.6 Million (Free Float 72.0%), Foreign Ownership 25.7%
  • Key Financial Forecasts (2025 → 2026F → 2027F):
    • Revenue: KRW 13.27 Trillion → KRW 14.65 Trillion → KRW 19.19 Trillion
    • Operating Profit: KRW -1.72 Trillion → KRW -407.1 Billion (Loss Narrowed) → KRW 989.3 Billion (Turnaround)
    • Net Profit (Controlling): KRW -649.5 Billion → KRW 198.4 Billion (Turnaround) → KRW 1.50 Trillion
    • ROE: -3.2% → 0.9% → 6.7%
    • PER / PBR: -x / 1.0x → 212.6x / 1.9x → 28.0x / 1.8x
    • EV/EBITDA: 87.1x → 23.9x → 14.5x
    • Revisions: Earnings Forecast Revised Upward, Valuation Multiple Revised Upward

🚀 2. [Market Opportunities & Business Outlook]

  • 1Q26 Earnings Preview: Operating Loss is projected at KRW -254.5 Billion (Loss narrowing QoQ).
    • Mid-to-Large Batteries: Revenue of KRW 2.2 Trillion (QoQ -19%) and Operating Loss of KRW -189.4 Billion (Loss narrowed). In EV cells, despite top-line deceleration from the expiration of 4Q client compensation, higher shipment volumes are expected to drive narrower operating losses. In ESS, solid profitability (OPM 6.5%) is anticipated backed by high factory utilization in Korea and the US alongside AMPC recognition (KRW 91.5 Billion).
    • Small Batteries: Revenue up +5% QoQ with narrowed operating losses, driven by strong demand across new applications such as BBUs.
    • Electronic Materials: Revenue softening (-10% QoQ) on seasonal off-peak trends, while maintaining solid operating profitability (OPM 15%).
  • Second-Half Weighted Recovery & Medium-Term Drivers:
    • US Grid ESS Acceleration: US cumulative utility-scale ESS installations through February surged +119% YoY. North American manufacturing capacity is scheduled to expand from NCA 7.4GWh currently by adding 22GWh of LFP capacity by 1H27, propelling sequential quarterly earnings growth.
    • EV Line Recovery & Catalysts: Following EV estimate bottoming, plant utilization is expected to recover supported by European policies (IAA) and subsidies. Upside triggers include the potential Samsung Display stake monetization (book value KRW 11.2 Trillion) and all-solid-state battery mass production (2H27).

📝 Editor’s Comment (Perspective)

The analyst views Samsung SDI as a turnaround battery manufacturer navigating past the bottom of EV earnings downgrades, entering a structural recovery path by proactively executing line conversions (EV to ESS) to capture surging US utility-scale ESS demand and new data center BBU volume. This perspective highlights the multi-year capacity buildout in North America (adding 22GWh of LFP capacity by 1H27 on top of NCA 7.4GWh) and European EV plant utilization recovery, rather than transient margin friction from expired 1Q compensation.

To evaluate the ongoing validity of this investment thesis, key monitoring factors include new order momentum aligned with rapid US utility ESS installation growth, the on-schedule commercial ramp-up of the North American LFP ESS capacity (22GWh) by 1H27 with associated AMPC generation, and the tangible rebound in European plant utilization in 2H26. These operational milestones can be tracked through upcoming quarterly financial releases, official company IR presentations, and periodic statutory filings.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, EV & Battery

Post navigation

Previous Post: [Research] SK hynix (000660 / SKHY) – IBK Securities | AI Servers · Server DRAM · Supply Tightness / 2026-04-15
Next Post: [IR] SK hynix (000660 / SKHY) – Q1 2026 Earnings Presentation / 2026-04-23

Related Posts

  • [Research] Samsung SDI (006400) – Kiwoom Securities | Near-Term Sluggishness but Intact Momentum · 4Q26 Turnaround · Solid-State Pipeline / 2026-02-03 Research
  • [Research] SK hynix (000660 / SKHY) – Kiwoom | Commodity Memory Pricing · HBM4 · Valuation Appeal / 2026-07-30 Research
  • [Research] Samsung Biologics (207940) – iM Securities | New Plant Operations · PolyPeptide Acquisition · Portfolio Diversification / 2026-07-24 Research
  • [Research] Samsung Electro-Mechanics (009150) – Daishin Securities | Supply Shortage · High-End Mix · Earnings Upward Cycle / 2026-07-31 Research
  • [Research] LigaChem Biosciences (141080) – Mirae Asset Securities | Clinical Milestones · Commercialization Potential · Platform PoC / 2025-05-23 Research
  • [Research] SK hynix (000660 / SKHY) – Daishin | Memory ASP · Earnings Upgrades · Valuation Appeal / 2026-03-16 Research
  • [Research] LIG D&A (079550) – SK Securities | Modern Warfare Leader · Limited Global CapEx · Multiple Re-rating / 2026-04-07 Research
  • [Research] LIG D&A (079550) – Daishin Securities | 1Q26 Review · Earnings Surprise · Export Diversification / 2026-05-08 Research
  • [Research] Samsung Electro-Mechanics (009150) – Yuanta Securities | MLCC Price Cycle · Customer Prepayments · Server Demand / 2026-08-11 Research
  • [Research] Samsung Biologics (207940) – Shinhan Securities | Capacity Expansion · Peptide Entry · Guidance Upgrade / 2026-07-24 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | AI Data Center Backlogs · LTA · Earnings Visibility / 2026-05-11 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q3 2025 Earnings Presentation / 2025-10-29 IR Room
  • [Research] LIG D&A (079550) – Yuanta Securities | Cheongung-II Demand Surge · OPM Guidance Upgrade · Middle East Overlap / 2026-08-07 Research
  • [Research] Samsung Biologics (207940) – Hana Securities | Post-Spinoff Profitability · Record KRW 6.8T Orders · Plant 6 Groundbreaking Visibility / 2026-01-07 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme